RNAC Stock Overview
A clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cartesian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.94 |
| 52 Week High | US$42.60 |
| 52 Week Low | US$11.67 |
| Beta | 0 |
| 11 Month Change | -24.88% |
| 3 Month Change | 26.70% |
| 1 Year Change | -53.72% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.23% |
Recent News & Updates
Cartesian Therapeutics: Uncertainty Remains
Nov 10Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Sep 17Shareholder Returns
| RNAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.1% | -6.5% | -1.0% |
| 1Y | -53.7% | 14.6% | 30.3% |
Return vs Industry: RNAC underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: RNAC underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| RNAC volatility | |
|---|---|
| RNAC Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNAC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNAC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 38 | Carsten Brunn | www.cartesiantherapeutics.com |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. Fundamentals Summary
| RNAC fundamental statistics | |
|---|---|
| Market cap | US$446.03m |
| Earnings (TTM) | -US$282.38m |
| Revenue (TTM) | US$47.94m |
9.0x
P/S Ratio-1.5x
P/E RatioIs RNAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAC income statement (TTM) | |
|---|---|
| Revenue | US$47.94m |
| Cost of Revenue | US$49.83m |
| Gross Profit | -US$1.89m |
| Other Expenses | US$280.49m |
| Earnings | -US$282.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.11 |
| Gross Margin | -3.95% |
| Net Profit Margin | -589.05% |
| Debt/Equity Ratio | 0% |
How did RNAC perform over the long term?
See historical performance and comparison